DGT, a novel heterocyclic diterpenoid, effectively suppresses psoriasis via inhibition of STAT3 phosphorylation

Gang Bian,Lidan Wang,Qing Xie,Yanping Wang,Haimei Feng,Yunhui Yu,Zijun Chen,Shiping Deng,Yunsen Li
DOI: https://doi.org/10.1111/bph.15306
IF: 7.3
2020-12-02
British Journal of Pharmacology
Abstract:Background and PurposePsoriasis is a chronic immune‐mediated inflammatory skin disease that easily recurs and is difficult to cure. DGT is a novel synthesized heterocyclic diterpenoid, whose structure has not been previously reported. Hence, we investigated the potent therapeutic activity of DGT against psoriasis, specifically the hyperproliferation of epidermal keratinocytes, angiogenesis and pathogenic inflammatory responses. Experimental DesignWe identified its pharmacokinetics in skin after topical administration. We characterized its therapeutic properties in vitro and in vivo using cell proliferation assay, cell apoptosis assay, diethylstilbestrol‐induced mouse vaginal epithelial cell mitosis model, tube formation assay, cell migration assay, chick embryonic chorioallantoic membrane (CAM) assay, histological, flow cytometric analysis, imiquimod (IMQ)‐ induced psoriasis‐like model. Key ResultsDGT was mainly distributed in the epidermis and dermis, which indicated that DGT was suitable as a topical treatment. DGT inhibited cell proliferation and induced apoptotic cell death of keratinocytes in vitro and in vivo. Moreover, DGT inhibited endothelial cell proliferation, tube formation and migration of in vitro angiogenesis, as well as in vivo CAM angiogenesis. In an IMQ‐induced psoriasis‐like skin inflammation murine model, topical administration of DGT ameliorated keratinocyte proliferation and inflammatory response, especially IL‐17–related psoriasiform dermatitis. Furthermore, our results identified that DGT prevented these pathological processes of psoriasis through suppression of STAT3 phosphorylation. Conclusion and ImplicationDGT shows great potential as a novel therapeutic agent for the treatment of psoriatic skin disease.
pharmacology & pharmacy
What problem does this paper attempt to address?